Optimizing treatment for elderly patients with acute promyelocytic leukemia: is it time to replace chemotherapy with all-trans retinoic acid and arsenic trioxide?

References

• Gilliland D G, Jordan C T, Felix C A. The molecular basis of leukemia. Hematology (Am Soc Hematol Educ Program) 2004; 80–97
   PubMedGoogle Scholar
• Huang M E, Ye Y C, Chen S R, Chai J R, Lu J X, Zhoa L, et al. Use of all-trans retinoic acid in the treatment of acute promyelocytic leukemia. Blood 1988; 72: 567–572
   PubMed Web of Science ®Google Scholar
• Mathews V, George B, Lakshmi K M, Viswabandya A, Bajel A, Balasubramanian P, et al. Single-agent arsenic trioxide in the treatment of newly diagnosed acute promyelocytic leukemia: durable remissions with minimal toxicity. Blood 2006; 107: 2627–2632
   PubMed Web of Science ®Google Scholar
• Shen Z X, Chen G Q, Ni J H, Li X S, Xiong S M, Qiu Q Y, et al. Use of arsenic trioxide (As2O3) in the treatment of acute promyelocytic leukemia (APL): II. Clinical efficacy and pharmacokinetics in relapsed patients. Blood 1997; 89: 3354–3360
   PubMed Web of Science ®Google Scholar
• Niu C, Yan H, Yu T, Sun H P, Liu J X, Li X S, et al. Studies on treatment of acute promyelocytic leukemia with arsenic trioxide: remission induction, follow-up, and molecular monitoring in 11 newly diagnosed and 47 relapsed acute promyelocytic leukemia patients. Blood 1999; 94: 3315–3324
   PubMed Web of Science ®Google Scholar
• Soignet S L, Maslak P, Wang Z G, Jhanwar S, Calleja E, Dardashti L J, et al. Complete remission after treatment of acute promyelocytic leukemia with arsenic trioxide. N Engl J Med 1998; 339: 1341–1348
   PubMed Web of Science ®Google Scholar
• Soignet S L, Frankel S R, Douer D, Tallman M S, Kantarjian H, Calleja E, et al. United States multicenter study of arsenic trioxide in relapsed acute promyelocytic leukemia. J Clin Oncol 2001; 19: 3852–3860
   PubMed Web of Science ®Google Scholar
• Ohnishi K, Yoshida H, Shigeno K, Nakamura S, Fujisawa S, Naito K, et al. Arsenic trioxide therapy for relapsed or refractory Japanese patients with acute promyelocytic leukemia: need for careful electrocardiogram monitoring. Leukemia 2002; 16: 617–622
   PubMed Web of Science ®Google Scholar
• Lazo G, Kantarjian H, Estey E, Thomas D, O'Brien S, Cortes J. Use of arsenic trioxide (As2O3) in the treatment of patients with acute promyelocytic leukemia: the MD Anderson experience. Cancer 2003; 97: 2218–2224
   PubMed Web of Science ®Google Scholar
• Petti M C, Pinazzi M B, Diverio D, Romano A, Petrucci M T, De Santis S, et al. Prolonged molecular remission in advanced acute promyelocytic leukaemia after treatment with gemtuzumab ozogamicin (Mylotarg CMA-676). Br J Haematol 2001; 115: 63–65
   PubMed Web of Science ®Google Scholar
• Estey E H, Giles F J, Beran M, O'Brien S, Pierce S A, Faderl S H, et al. Experience with gemtuzumab ozogamycin (‘mylotarg’) and all-trans retinoic acid in untreated acute promyelocytic leukemia. Blood 2002; 99: 4222–4224
   PubMed Web of Science ®Google Scholar
• Tsimberidou A M, Estey E, Whitman G J, Dryden M J, Ratnam S, Pierce S, et al. Extramedullary relapse in a patient with acute promyelocytic leukemia: successful treatment with arsenic trioxide, all-trans retinoic acid and gemtuzumab ozogamicin therapies. Leuk Res 2004; 28: 991–994
   PubMed Web of Science ®Google Scholar
• Lo Coco F, Ammatuna E, Noguera N. Treatment of acute promyelocytic leukemia with gemtuzumab ozogamicin. Clin Adv Hematol Oncol 2006; 4: 57–62
   PubMedGoogle Scholar
• Estey E, Koller C, Tsimberidou A M, O'Brien S, Beran M, Cortes J, et al. Potential curability of newly diagnosed acute promyelocytic leukemia without use of chemotherapy: the example of liposomal all-trans retinoic acid. Blood 2005; 105: 1366–1367
   PubMed Web of Science ®Google Scholar
• Douer D, Tallman M S. Arsenic trioxide: new clinical experience with an old medication in hematologic malignancies. J Clin Oncol 2005; 23: 2396–2410
   PubMed Web of Science ®Google Scholar
• de Botton S, Fawaz A, Chevret S, Dombret H, Thomas X, Sanz M, et al. Autologous and allogeneic stem-cell transplantation as salvage treatment of acute promyelocytic leukemia initially treated with all-trans-retinoic acid: a retrospective analysis of the European acute promyelocytic leukemia group. J Clin Oncol 2005; 23: 120–126
   PubMed Web of Science ®Google Scholar
• Lo-Coco F, Romano A, Mengarelli A, Diverio D, Iori A P, Moleti M L, et al. Allogeneic stem cell transplantation for advanced acute promyelocytic leukemia: results in patients treated in second molecular remission or with molecularly persistent disease. Leukemia 2003; 17: 1930–1933
   PubMed Web of Science ®Google Scholar
• Thomas X, Dombret H, Cordonnier C, Pigneux A, Gardin C, Guerci A, et al. Treatment of relapsing acute promyelocytic leukemia by all-trans retinoic acid therapy followed by timed sequential chemotherapy and stem cell transplantation. APL Study Group. Acute promyelocytic leukemia. Leukemia 2000; 14: 1006–1013
   PubMed Web of Science ®Google Scholar
• Latagliata R, Avvisati G, Lo Coco F, Petti M C, Diverio D, Spadea A, et al. The role of all-trans-retinoic acid (ATRA) treatment in newly diagnosed acute promyelocytic leukemia patients aged >60 years. Ann Oncol 1997; 8: 1273–1275
   PubMed Web of Science ®Google Scholar
• Mandelli F, Latagliata R, Avvisati G, Fazi P, Rodeghiero F, Leoni F, et al. Treatment of elderly patients (>or = 60 years) with newly diagnosed acute promyelocytic leukemia. Results of the Italian multicenter group GIMEMA with ATRA and idarubicin (AIDA) protocols. Leukemia 2003; 17: 1085–1090
   PubMed Web of Science ®Google Scholar
• Ades L, Chevret S, De Botton S, Thomas X, Dombret H, Beve B, et al. Outcome of acute promyelocytic leukemia treated with all trans retinoic acid and chemotherapy in elderly patients: the European group experience. Leukemia 2005; 19: 230–233
   PubMed Web of Science ®Google Scholar
• Sanz M A, Vellenga E, Rayon C, Diaz-Mediavilla J, Rivas C, Amutio E, et al. All-trans retinoic acid and anthracycline monochemotherapy for the treatment of elderly patients with acute promyelocytic leukemia. Blood 2004; 104: 3490–3493
   PubMed Web of Science ®Google Scholar
• Sanz M A, Lo Coco F, Martin G, Avvisati G, Rayon C, Barbui T, et al. Definition of relapse risk and role of nonanthracycline drugs for consolidation in patients with acute promyelocytic leukemia: a joint study of the PETHEMA and GIMEMA cooperative groups. Blood 2000; 96: 1247–1253
   PubMed Web of Science ®Google Scholar
• Sanz M A, Martin G, Rayon C, Esteve J, Gonzalez M, Diaz-Mediavilla J, et al. A modified AIDA protocol with anthracycline-based consolidation results in high antileukemic efficacy and reduced toxicity in newly diagnosed PML/RARalpha-positive acute promyelocytic leukemia. PETHEMA group. Blood 1999; 94: 3015–3021
   PubMed Web of Science ®Google Scholar
• Kanamaru A, Takemoto Y, Tanimoto M, Murakami H, Asou N, Kobayashi T, et al. All-trans retinoic acid for the treatment of newly diagnosed acute promyelocytic leukemia. Japan Adult Leukemia Study Group. Blood 1995; 85: 1202–1206
   PubMed Web of Science ®Google Scholar
• Fenaux P, Chastang C, Chevret S, Sanz M, Dombret H, Archimbaud E, et al. A randomized comparison of all transretinoic acid (ATRA) followed by chemotherapy and ATRA plus chemotherapy and the role of maintenance therapy in newly diagnosed acute promyelocytic leukemia. The European APL Group. Blood 1999; 94: 1192–1200
   PubMed Web of Science ®Google Scholar
• Fenaux P, Chevret S, de Botton S. Treatment of older adults with acute promyelocytic leukaemia. Best Pract Res Clin Haematol 2003; 16: 495–501
   PubMed Web of Science ®Google Scholar
• Gordon J A. Data requested from the subgroups studied in the APL93 trial. Blood 1999; 94: 3958
   PubMed Web of Science ®Google Scholar
• Estey E, Garcia-Manero G, Ferrajoli A, Faderl S, Verstovsek S, Jones D, et al. Use of all-trans retinoic acid + arsenic trioxide as an alternative to chemotherapy in untreated acute promyelocytic leukemia. Blood 2006; 107: 3469–3473
   PubMed Web of Science ®Google Scholar
• Estey E. Reducing mortality associated with immediate treatment complications of adult leukemias. Semin Hematol 2001; 38: 32–37
   PubMed Web of Science ®Google Scholar
• Burnett A K, Grimwade D, Solomon E, Wheatley K, Goldstone A H. Presenting white blood cell count and kinetics of molecular remission predict prognosis in acute promyelocytic leukemia treated with all-trans retinoic acid: result of the Randomized MRC Trial. Blood 1999; 93: 4131–4143
   PubMed Web of Science ®Google Scholar